Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03389347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Study completion date changed from estimate of Dec 19, 2026 to Jul 24, 2026 · Eligibility criteria expanded, about 27 words · Secondary endpoints: details revised at 1 of 1 entry · 1 more Show 4 more changesShow less
    • Study completion date changed from estimate of Dec 19, 2026 to Jul 24, 2026
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Results first posted: May 8, 2026v21
  3. Primary endpoint revisedv20 See this version in full on ClinicalTrials.gov ↗
  4. Secondary endpoint revised Primary endpoint revisedv19 Show 1 more changeShow less
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  5. Re-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Jun 1, 2025 to Dec 19, 2024 · Completion date: Jun 1, 2027 to Dec 19, 2026 · Site details revisedv17 Show 3 more changesShow less
    • Primary completion date changed from estimate of Jun 1, 2025 to Dec 19, 2024
    • Completion date: Jun 1, 2027 to Dec 19, 2026
    • Site details revised
  2. Re-verified, no change to tracked fieldsv16
  3. Enrollment target: 30 to 40 Eligibility criteria expanded, about 32 words · Site contact updatedv15 Show 2 more changesShow less
    • Eligibility criteria expanded, about 32 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Jun 1, 2024 to Jun 1, 2025 Completion date: Jun 1, 2026 to Jun 1, 2027v14 Show 1 more changeShow less
    • Completion date: Jun 1, 2026 to Jun 1, 2027
  5. Trial status: Suspended to Recruiting Site details revisedv13 Show 1 more changeShow less
    • Site details revised
  6. Trial status: Recruiting to Suspended Sponsor's reason: Study is on hold pending protocol modification Site details revisedv12 Show 1 more changeShow less
    • Site details revised
  7. Primary completion date: Jun 1, 2023 to Jun 1, 2024 Completion date: Jun 1, 2025 to Jun 1, 2026v11 Show 1 more changeShow less
    • Completion date: Jun 1, 2025 to Jun 1, 2026
  8. Re-verified, no change to tracked fieldsv10
  9. Study description shortened, about 74 wordsv9 See this version in full on ClinicalTrials.gov ↗
  10. Primary completion date: Jun 1, 2022 to Jun 1, 2023 Completion date: Jun 1, 2024 to Jun 1, 2025 · Collaborators shortened, about 4 wordsv8 Show 2 more changesShow less
    • Completion date: Jun 1, 2024 to Jun 1, 2025
    • Collaborators shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  11. Primary completion date: Jun 1, 2021 to Jun 1, 2022 Completion date: Jun 1, 2023 to Jun 1, 2024v7 Show 1 more changeShow less
    • Completion date: Jun 1, 2023 to Jun 1, 2024
  12. Enrollment target: 15 to 30 Secondary endpoint revised · Study description revisedv6 Show 2 more changesShow less
    • Secondary endpoint revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  13. Primary completion date: Jun 1, 2020 to Jun 1, 2021 Completion date: May 1, 2022 to Jun 1, 2023v5 Show 1 more changeShow less
    • Completion date: May 1, 2022 to Jun 1, 2023
  14. Start date: Mar 19, 2018 to Feb 14, 2018 Eligibility criteria shortened, about 2 wordsv4 Show 1 more changeShow less
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  15. Start date changed from estimate of May 1, 2018 to Mar 19, 2018 Interventions: Biospecimen Collection (Procedure), High-throughput assay (Device), Laboratory Biomarker Analysis (Other) to Biospecimen Collection (Procedure), High Throughput Screening (Device), Laboratory Biomarker Analysis (Other) · Eligibility criteria expanded, about 21 wordsv3 Show 2 more changesShow less
    • Interventions: Biospecimen Collection (Procedure), High-throughput assay (Device), Laboratory Biomarker Analysis (Other) to Biospecimen Collection (Procedure), High Throughput Screening (Device), Laboratory Biomarker Analysis (Other)
    • Eligibility criteria expanded, about 21 words

    See this version in full on ClinicalTrials.gov ↗

  16. Trial status: Not Yet Recruiting to Recruiting Start date: Feb 1, 2018 to May 1, 2018 · Primary completion date: Mar 1, 2020 to Jun 1, 2020 · Completion date: Feb 1, 2022 to May 1, 2022 · 1 morev2 Show 4 more changesShow less
    • Start date: Feb 1, 2018 to May 1, 2018
    • Primary completion date: Mar 1, 2020 to Jun 1, 2020
    • Completion date: Feb 1, 2022 to May 1, 2022
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or plasma cell leukemia that has come back or does not respond to treatment. High throughput screen tests many different drugs that kill multiple myeloma cells in individual chambers at the same time. Matching a drug or drug combination to a patient using high throughput screen and genetic information may improve the ability to help patients by choosing drugs that work well for their disease.
Trial Details
NCT Number NCT03389347
Lead Sponsor University of Washington
Conditions Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov